abrdn Life Sciences Investors
HQL
55 hedge funds and large institutions have $53.3M invested in abrdn Life Sciences Investors in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 8 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 16
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
0.62% less ownership
Funds ownership: 14.53% → 13.91% (-0.62%)
3% less capital invested
Capital invested by funds: $54.8M → $53.3M (-$1.44M)
2% less funds holding
Funds holding: 56 → 55 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$1.32M |
| 2 |
AAM
Advisors Asset Management
Monument,
Colorado
|
+$741K |
| 3 |
AUB
Atlantic Union Bankshares
Glen Allen,
Virginia
|
+$362K |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$321K |
| 5 |
MIAN
Mariner Independent Advisor Network
Overland Park,
Kansas
|
+$246K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$1.01M |
| 2 |
CRC
Curi RMB Capital
Chicago,
Illinois
|
-$781K |
| 3 |
TJHA
Thomas J. Herzfeld Advisors
Miami Beach,
Florida
|
-$678K |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$396K |
| 5 |
Millennium Management
New York
|
-$282K |
HQL Hedge Fund Activity: Q2 2019 in Review
55 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2019, worth a combined $53.3M — down 2.6% from $54.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new HQL positions and 8 closed out — a net gain of 1 holder — while 20 added to existing stakes and 16 trimmed.
The largest buyer was 1832 Asset Management, opening a new position worth an estimated $1.32M. The largest seller was Raymond James & Associates, cutting an estimated $1.01M.
- 55 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2019, down from 56 in Q1 2019.
- Funds reported $53.3M of abrdn Life Sciences Investors stock for Q2 2019, down 2.6% quarter-over-quarter.
- 9 funds opened new abrdn Life Sciences Investors positions in Q2 2019 and 8 closed out, a net change of +1 holder.
- The largest abrdn Life Sciences Investors buyer in Q2 2019 was 1832 Asset Management, an estimated $1.32M added.
- The largest abrdn Life Sciences Investors seller in Q2 2019 was Raymond James & Associates, an estimated $1.01M sold.
Based on aggregated 13F filings for Q2 2019.